Viridian Therapeutics (NASDAQ:VRDN) Insider Jennifer Tousignant Sells 14,212 Shares of Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) insider Jennifer Tousignant sold 14,212 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $24.50 on Friday. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43. The stock has a market cap of $2.78 billion, a PE ratio of -7.27 and a beta of 0.91. The firm’s fifty day simple moving average is $19.66 and its 200-day simple moving average is $20.97.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). The business had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. Analysts expect that Viridian Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRDN has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price objective on shares of Viridian Therapeutics in a research report on Monday, June 29th. Stifel Nicolaus set a $39.00 target price on Viridian Therapeutics in a report on Wednesday, May 13th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $39.00 price target on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Wall Street Zen lowered Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Finally, Wells Fargo & Company upgraded Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $20.00 to $31.00 in a research report on Monday, June 29th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Viridian Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $38.93.

Hedge Funds Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Viridian Therapeutics by 29.6% during the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after purchasing an additional 1,280,161 shares during the period. Commodore Capital LP raised its position in Viridian Therapeutics by 35.4% in the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares during the last quarter. State Street Corp lifted its position in Viridian Therapeutics by 35.7% during the 4th quarter. State Street Corp now owns 3,466,560 shares of the company’s stock worth $107,879,000 after buying an additional 912,394 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Viridian Therapeutics by 42.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company’s stock valued at $107,036,000 after purchasing an additional 1,021,310 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Viridian Therapeutics by 1.6% in the second quarter. Wellington Management Group LLP now owns 3,128,362 shares of the company’s stock valued at $57,468,000 after acquiring an additional 49,808 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.